The field of pet diabetes management is becoming the fastest emerging segment in the practice of veterinary medicine due to the increase in diabetes prevalence in dogs and cats caused by obesity, physical inactivity, and longer lives of pets.
These trends have led to a rethinking of how pet owners and veterinarians manage chronic diseases. Higher humanization of pets, increased willingness to invest in the use of advanced treatment, and better access to advanced continuous glucose monitoring and nutrition are the major factors behind the growth in the application of advanced diabetes management programs. According to a report by Boehringer Ingelheim from January 2025, the prevalence of diabetes among cats is about 1 in 200 and among dogs is about 1 in 300 across the globe, increasing by 6% per year.
The U.S. Pet Diabetes Care Market was valued at approximately USD 727.33 million in 2024 and is projected to reach around USD 1,414.86 million by 2032, driven by high pet ownership, expanding pet humanization, strong veterinary service penetration, and growing willingness among American pet owners to invest in advanced diabetes management. Globally, the Pet Diabetes Care Market was valued at USD 2.07 billion in 2024 and is expected to reach USD 4.08 billion by 2032, expanding at a CAGR of 8.87% during the forecast period of 2025–2032.
Gain Actionable Intelligence on the Pet Diabetes Care Market - Request a Sample Report
U.S. Pet Diabetes Care Market Analysis
The dominance of the U.S. in the market for pet diabetes care can be explained by high rates of pet ownership, strong veterinary service development and increasing tendencies of humanization of pets. Americans see diabetes care management as one of the aspects of responsible pet owners care and, therefore, need insulin, glucose monitoring and special nutrition.
Increasing veterinary sector development and telemedicine are among main factors contributing to the growth of the U.S. market. Growing number of veterinary endocrinologists and specialty clinics helps to improve diagnostics and treatment processes of diabetes and other diseases, while tele-veterinary services give an opportunity to monitor pets' state remotely to those pet owners who live in remote locations. In February 2025, TeleVet Insights reported that remote consultations about chronic conditions of pets, including diabetes, increased by 18% in the U.S.
Developing glucose monitoring technology can serve as another driver for the growth of the U.S. market. Continuous glucose monitors and wearables help pet owners to control the glucose level at any moment and provide veterinarians with more prescriptive insights into each pet's condition.
Top 5 Leading Companies in the Pet Diabetes Care Market
1. Boehringer Ingelheim Animal Health
Boehringer Ingelheim is the leader in pet diabetes care by offering scientifically backed products designed for state-of-the-art veterinary treatment. Boehringer Ingelheim introduced its latest version of a continuous glucose monitor for pets in June 2024 to improve diabetes management and patient compliance around the world.
The high R&D emphasis and global presence of the firm make it an important player in the development of insulin treatments and glucose monitors in the U.S. market.
2. Merck Animal Health
Merck is the manufacturer of innovative insulins and diagnostic products to better help pets cope with diabetes. The company launched a sustained-release insulin product for dogs in September 2024 that helps reduce the need for injections and improve glycemic control for dogs.
Heavy investments in the veterinary sphere continue to help Merck become more prominent in the field of diabetic pets treatment in the USA.
3. Elanco Animal Health
Elanco provides products that include diabetes drug, nutrition, and pet therapeutics. In March 2025, Elanco collaborated with a biotech company to develop oral antidiabetics for dogs and cats. Strategic collaborations enable Elanco to provide greater access to diabetes therapy.
Elanco’s partnerships and technological innovation support the provision of diabetes therapy in the international and domestic marketplaces.
3. Zoetis Inc.
Zoetis is a key player in the U.S. animal health industry, contributing to the provision of diagnostic and therapeutic products for veterinarians that are useful in the treatment of chronic conditions such as diabetes.
The company’s continued focus on veterinary diagnostic and monitoring technologies matches the trend towards a more data-driven approach to diabetes treatment.
5. Abbott Laboratories
Abbott occupies a prominent position in the market for glucose monitoring products in the diabetic pets’ management market because of the company’s competence in the field of diagnostics and monitoring technologies. It helps to enhance the adoption rate of at-home and point-of-care glucose monitoring systems for pets suffering from diabetes.
The company’s broad experience in the diagnostics field enhances the development of continuous glucose monitoring adoption infrastructure in the U.S. veterinary hospitals and homes.
What the Future of the Pet Diabetes Care Market Holds
The future of the pet diabetes care market will be defined by advancements in specialist treatments, integration of smart devices, and personalization of care. Further advancement of specialized insulin, oral antidiabetics, and continuous glucose monitoring technologies for pets will be likely to enhance efficiency of the treatment process.
In addition to wider use of wearable glucose meters, smart insulin pens, and mobile applications for treatment monitoring, cooperation between veterinary hospitals, biotechnological companies, and pet health care manufacturers will result in the creation of new products. The introduction of new delivery technologies like sustained-release insulin and glucose monitor patches will also contribute to the convenience of diabetes treatment for both animals and their owners.
North America will be expected to hold the leading position on the pet diabetes care market due to the high level of pet ownership, developed system of veterinary clinics and growing tendencies towards humanization in the region. North America will account for 41.72% of the global market revenue in 2024. The US will retain its leadership until 2032 and beyond.
